Table 1. Demographics and Clinical Characteristics of the Patients.
| Training set (n=51) | External validation set (n=51) | p value | ||
|---|---|---|---|---|
| Age (yr) | 49.8±9.1 | 51.8±10.3 | 0.306 | |
| Interval between MRI and operation (day) | 6.2± 6.0 | 6.3±5.6 | 0.959 | |
| Size of brain lesion (mm3)* | 8106.4 (5254.2–15226.6) | 14786.8 (9901.2–26713.6) | <0.001 | |
| Location | 0.033 | |||
| Cerebellum | 15 (29.4) | 23 (45.1) | ||
| Deep gray matter | 5 (9.8) | 0 (0.0) | ||
| Cerebral lobes | 31 (60.8) | 28 (54.9) | ||
| Molecular subtype of brain lesion | 0.573 | |||
| HR+/HER2- | 9 (17.6) | 15 (29.4) | ||
| HR+/HER2+ | 7 (13.7) | 6 (11.8) | ||
| HR-/HER2+ | 19 (37.3) | 17 (33.3) | ||
| TN | 16 (31.4) | 13 (25.5) | ||
| Molecular subtype of primary lesion | 0.174 | |||
| HR+/HER2- | 8 (15.7) | 17 (33.3) | ||
| HR+/HER2+ | 12 (23.5) | 8 (15.7) | ||
| HR-/HER2+ | 16 (31.4) | 11 (21.6) | ||
| TN | 15 (29.4) | 15 (29.4) | ||
| Molecular subtype conversion | 13 (25.5) | 12 (23.5) | >0.999 | |
HR, hormone receptor; HER2, human epidermal growth factor receptor 2; TN, triple negative.
*The size of the brain metastatic lesions on which the radiomics study was performed is reported using the median value and interquartile range after undergoing a normality test. A comparison between the two median values was performed using the Mann-Whitney test.